Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2022-02-11 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure Partner Asieris announces Approval to conduct a Phase III Clinical Trial for Hexvix in China
Regulatory Filings Classification · 100% confidence The document is a press release from Photocure ASA announcing that its partner, Asieris Pharmaceuticals, received approval from the Chinese NMPA to conduct a Phase III clinical trial for Hexvix. This type of announcement, detailing clinical trial progress, regulatory milestones, and partnership updates, is characteristic of general corporate news intended for investors and the public. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement that doesn't fit the highly specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend Notice (DIV), the most appropriate classification is the general regulatory announcement/press release category, RNS, which serves as a broad category for such disclosures.
2022-02-11 English
Major shareholder disclosure in Photocure ASA
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled "Standard form for notification of major holdings" and details changes in voting rights percentages (crossing thresholds from 5.20% to 4.56%) by a shareholder (Skandinaviska Enskilda Banken AB (publ)) in an issuer (Photocure ASA). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER/MDA: Not an earnings release or management discussion. - DIRS: This is about director trades, not general major shareholder changes. - The document perfectly matches the description for Major Shareholding Notification (Code: MRQ).
2022-02-08 English
Major shareholder disclosure in Photocure ASA
Major Shareholding Notification Classification · 95% confidence The document text is extremely short (137 characters) and explicitly states 'Please see attachment on www.newsweb.no'. This indicates the document is an announcement pointing to the actual filing, not the filing itself. The content mentions 'Major shareholder disclosure'. This strongly aligns with the definition of a Major Shareholding Notification (MRQ), which reports changes in significant share ownership levels. Since this is a brief announcement pointing elsewhere, the Report Publication Announcement (RPA) or Regulatory Filing (RNS) might be considered, but given the specific subject matter ('Major shareholder disclosure'), MRQ is the most accurate content classification, and the short length suggests it's the announcement of that disclosure.
2022-02-08 English
Bladder Cancer technology: New improved Blue Light Cystoscopy system receives FDA approval for use in NMIBC in the U.S.
Regulatory Filings Classification · 95% confidence The document is a press release dated February 7, 2022, announcing that Photocure ASA's partner, KARL STORZ, received FDA approval for an improved Blue Light Cystoscopy system to be used with Cysview® for NMIBC detection. This type of announcement, detailing a significant business event (regulatory approval) and providing context, quotes, and company background, is characteristic of an Earnings Release (ER) or a general press release that doesn't fit other specific categories. Since it is an initial announcement of a key event (FDA approval) rather than a comprehensive periodic financial report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate fit among the provided options for a significant, timely corporate announcement, although 'RNS' (Regulatory Filings) is also plausible as a general announcement. Given the content focuses on a major product/regulatory milestone, ER is often used for such material news releases, but since it is not explicitly an earnings report, and it is a specific regulatory event announcement, 'RNS' (Regulatory Filings - general regulatory announcements/fallback) is a safer classification if ER is strictly reserved for quarterly/annual financial results summaries. However, many companies use ER for major news. Let's re-evaluate based on definitions. It is not a CT, IP, or MDA. It is a press release announcing a regulatory event. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a regulatory approval announcement, it fits best under the general 'RNS' (Regulatory Filings) category, which serves as the fallback for miscellaneous filings that do not neatly fit elsewhere, especially when the core content is a press release about a specific event rather than financial performance highlights.
2022-02-07 English
Bladder Cancer technology: New improved Blue Light Cystoscopy system receives FDA approval for use in NMIBC in the U.S.
Regulatory Filings Classification · 100% confidence The document is a press release dated February 7, 2022, announcing that Photocure ASA's partner, KARL STORZ, received FDA approval for an improved Blue Light Cystoscopy system to be used with Cysview® for detecting NMIBC. This type of announcement, detailing a significant business event (regulatory approval) via a press release format, is typically classified as an Earnings Release (ER) if it were tied to financial results, or more generally as a Regulatory Filing (RNS) if it's a broad announcement not fitting other specific categories. Since it is a specific, non-financial-result-focused announcement about a regulatory milestone (FDA approval) and partnership update, it fits best under the general 'Regulatory Filings' (RNS) category, as it is not a full report (10-K, IR), a management discussion (MDA), or a specific capital/dividend event. It is an announcement, but not explicitly an 'Earnings Release' (ER) as it doesn't contain financial figures, nor is it a 'Report Publication Announcement' (RPA) as it is announcing an approval, not the publication of a periodic report.
2022-02-07 English
Photocure ASA – Major shareholding disclosure
Major Shareholding Notification Classification · 98% confidence The document explicitly states it is a 'Major shareholding disclosure' concerning a change in ownership percentage (10.14%) by an entity (Briarwood Chase Management LLC). This directly corresponds to the definition of 'Major Shareholding Notification' (Code: MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2022-02-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.